Literature DB >> 9000640

DNA vaccines.

J J Donnelly1, J B Ulmer, M A Liu.   

Abstract

Immunization with plasmid DNA encoding antigenic proteins elicits both antibody and cell-mediated immune responses. This method of producing the protein antigens of interest directly in host cells can provide appropriate tertiary structure for the induction of conformationally specific antibodies, and also facilitates the induction of cellular immune responses. DNA immunization has provided effective protective immunity in various animal models. The immune responses induced by DNA vaccines may in some instances be preferable to those produced by immunization using conventional methods. DNA vaccination appears to be applicable to a variety of pathogens and is a useful method of raising immune responses. Thus this approach to vaccination has the potential to be a successful method of rapidly screening for antigens capable of inducing protective immunity, and of inducing protective immunity against pathogens of clinical importance.

Mesh:

Substances:

Year:  1997        PMID: 9000640     DOI: 10.1016/s0024-3205(96)00502-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  42 in total

1.  Cationic microparticles: A potent delivery system for DNA vaccines.

Authors:  M Singh; M Briones; G Ott; D O'Hagan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 2.  Plasmid DNA vaccines. Immunology, tolerance, and autoimmunity.

Authors:  G Mor; M Eliza
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

3.  DNA-based vaccination induces humoral and cellular immune responses against hepatitis B virus surface antigen in mice without activation of C-myc.

Authors:  Lian-San Zhao; Shan Qin; Tao-You Zhou; Hong Tang; Li Liu; Bing-Jun Lei
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

4.  The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery.

Authors:  M Briones; M Singh; M Ugozzoli; J Kazzaz; S Klakamp; G Ott; D O'Hagan
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

5.  C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis.

Authors:  S Youssef; G Maor; G Wildbaum; N Grabie; A Gour-Lavie; N Karin
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

6.  The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance.

Authors:  Manmohan Singh; Mildred Ugozzoli; Maylene Briones; Jina Kazzaz; Elawati Soenawan; Derek T O'Hagan
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

7.  Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device.

Authors:  Dinah H Amante; Trevor R F Smith; Janess M Mendoza; Katherine Schultheis; Jay R McCoy; Amir S Khan; Niranjan Y Sardesai; Kate E Broderick
Journal:  Hum Gene Ther Methods       Date:  2015-08       Impact factor: 2.396

Review 8.  Poly-N-acetyl glucosamine gel matrix as a non-viral delivery vector for DNA-based vaccination.

Authors:  Mohamed L Salem; Marina Demcheva; William E Gillanders; David J Cole; John N Vournakis
Journal:  Anticancer Res       Date:  2010-10       Impact factor: 2.480

9.  DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Authors:  Margherita Rosati; Agneta von Gegerfelt; Patricia Roth; Candido Alicea; Antonio Valentin; Marjorie Robert-Guroff; David Venzon; David C Montefiori; Phil Markham; Barbara K Felber; George N Pavlakis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

10.  Neonatal DNA immunization with a plasmid encoding an internal viral protein is effective in the presence of maternal antibodies and protects against subsequent viral challenge.

Authors:  D E Hassett; J Zhang; J L Whitton
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.